Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ferroptosis-Associated Fibroblast Activation and Transcriptional Remodelling in Human Heart Failure: A Proof-of-Concept Study.

European journal of clinical investigation·2026
Same author

Ferroptosis in heart failure: from molecular insights to therapeutic implications.

Cardiovascular research·2026
Same author

Hellenic Postprandial Lipemia Study (HPLS): A Prospective Cohort Trial on the Effect of Statins on Postprandial Hypertriglyceridemia.

Current vascular pharmacology·2026
Same author

Lomitapide response in a cohort of patients with homozygous familial hypercholesterolemia and the potential influence of MTTP gene variants.

Orphanet journal of rare diseases·2025
Same author

HDL cholesterol as an associate of prevalent coronary artery disease in heterozygous Familial hypercholesterolemia beyond LDL cholesterol.

Endocrine·2025
Same author

Beyond lipid levels: unraveling the hypertensive factor in familial hypercholesterolemia. The HELLAS-FH registry.

Journal of human hypertension·2025

Related Experiment Videos

Gene polymorphisms and thyroid function in patients with heart failure.

Ioannis Vasiliadis1, Genovefa Kolovou, Vana Kolovou

  • 1Cardiology Department, Onassis Cardiac Surgery Center Athens, 356 Sygrou Ave, 176 74, Athens, Greece.

Endocrine
|April 2, 2013
PubMed
Summary
This summary is machine-generated.

This study found that thyroid hormones correlate with cardiovascular capacity in heart failure patients. Gene variations in nuclear factor kappa B (NFkB) and angiotensin converting enzyme (ACE) were associated with altered thyroid hormone levels.

Related Experiment Videos

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Genetics

Background:

  • Heart failure (HF) is associated with altered thyroid hormone levels.
  • Genetic factors may influence thyroid function in HF patients.

Purpose of the Study:

  • To investigate the correlation between nuclear factor kappa B (NFkB) and angiotensin converting enzyme (ACE) gene polymorphisms and thyroid function in patients with heart failure.
  • To assess the relationship between thyroid hormones and cardiovascular (CV) capacity, evaluated by peak oxygen uptake (VO(2)).

Main Methods:

  • 194 heart failure patients underwent cardiopulmonary exercise testing to determine peak VO(2) and Weber classification.
  • Blood samples were analyzed for thyroid-stimulating hormone, triiodothyronine (T3), thyroxine (T4), free T3 (FT3), and free T4 (FT4).
  • Patients were genotyped for NFkB (rs28362491) and ACE (rs1799752) polymorphisms.

Main Results:

  • Thyroid hormones showed significant correlations with CV capacity, with T3 increasing and FT3 decreasing as Weber classification worsened.
  • NFkB and ACE gene polymorphisms were associated with thyroid hormone levels: Del carriers had elevated FT3, II genotype had elevated T4, and D allele carriers had decreased T4 and FT4.

Conclusions:

  • Thyroid hormone levels are linked to cardiovascular capacity in heart failure.
  • Specific NFkB and ACE gene polymorphisms are associated with altered thyroid hormone profiles in HF patients.
  • Further research is needed to elucidate the genetic contributions to thyroid dysfunction in heart failure.